Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein

Roger Yazbeck, Simone E. Jaenisch, Catherine A. Abbott

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating critical biochemical pathways continues to emerge. The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers. The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer. Furthermore, the stability and persistence of soluble DPP4 and FAP in the serum make them attractive candidate serology markers. This review summarises investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clinically useful tools.

Original languageEnglish
Pages (from-to)375-386
Number of pages12
Issue number1
Early online date2017
Publication statusPublished - Jan 2018


  • Biomarker
  • Cancer
  • Dipeptidyl peptidase
  • Fibroblast activation protein
  • Inflammation


Dive into the research topics of 'Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein'. Together they form a unique fingerprint.

Cite this